Stocks › PCRX
Pacira BioSciences, Inc.
PCRX·Nasdaq·
United States·USD
United States·USD$24.76
-0.29 (-1.16%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
PCRX
Pacira BioSciences, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
PCRXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of PCRX by members of U.S. Congress · 17 on record
Whale Activity
Position changes in PCRX reported for 2026-06-30 by 9 tracked institutional filers
- Increased3
- New0
- Held0
- Decreased6
- Closed0
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 6.7M | $170.1M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.4M | $61.0M | decreased |
| D. E. Shaw & Co., Inc. | 2.0M | $49.5M | decreased |
| RENAISSANCE TECHNOLOGIES LLC | 1.7M | $44.0M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | $42.9M | decreased |
| TWO SIGMA INVESTMENTS, LP | 724.6K | $18.4M | increased |
| MILLENNIUM MANAGEMENT LLC | 235.2K | $6.0M | increased |
| BlackRock, Inc. | 6.0M | $5.9M | increased |
| CITADEL ADVISORS LLC | 162.2K | $4.1M | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by PCRX insiders, by quarter · Form 4
Recent Insider Transactions
1,157 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| SLONIN JONATHANChief Medical Officer | Sale | −3,040 | $23.23 | $71K | Aug 17, 2026 | Form 4 ↗ |
| RIKER LAURENSenior Vice President, Finance | Sale | −6,115 | $23.50 | $144K | Jun 11, 2026 | Form 4 ↗ |
| Hirawat SamitDirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| CHRISTIE CHRISTOPHERDirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| Young AlethiaDirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| YANG MICHAEL J.Director | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| BIGAL MARCELODirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| Froimson MarkDirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| Brege LauraDirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| WILLIAMS KRISTENChief Administrative Officer | Sale | −10.3K | $22.27 | $228K | Jun 4, 2026 | Form 4 ↗ |
| RIKER LAURENSenior Vice President, Finance | Tax withholding | −3,187 | $22.32 | $71K | Jun 3, 2026 | Form 4 ↗ |
| SLONIN JONATHANChief Medical Officer | Tax withholding | −4,728 | $22.32 | $106K | Jun 3, 2026 | Form 4 ↗ |
| WILLIAMS KRISTENChief Administrative Officer | Tax withholding | −8,528 | $22.32 | $190K | Jun 3, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Sale | −12.9K | $25.16 | $326K | Apr 23, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Option exercise | +12.9K | $16.45 | $213K | Apr 23, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Sale | −1,500 | $25.01 | $38K | Apr 22, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Option exercise | +1,500 | $16.45 | $25K | Apr 22, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Sale | −2,845 | $25.01 | $71K | Apr 21, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Option exercise | +2,845 | $16.45 | $47K | Apr 21, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Sale | −7,714 | $25.14 | $194K | Apr 20, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding PCRX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF iShares Trust | 2.4M | $60.2M | 0.05% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $30.4M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.0M | $26.2M | 0.03% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 856.2K | $21.7M | 0.01% | Jun 30, 2026 |
| Impax Small Cap Fund IMPAX FUNDS SERIES TRUST I | 750.0K | $19.0M | 2.00% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF American Century ETF Trust | 762.5K | $17.7M | 0.07% | May 31, 2026 |
| U.S. SMALL CAP VALUE PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 570.2K | $15.1M | 0.08% | Jul 31, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 542.9K | $13.8M | 0.02% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 453.8K | $11.5M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 432.5K | $11.4M | 0.03% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list PCRX's shares (CUSIP 695127100), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Pacira BioSciences, Inc. as client
No lobbying filings found naming Pacira BioSciences, Inc. as the client.
Government Contracts
Federal awards to Pacira BioSciences, Inc. · USAspending
No federal contract awards found for Pacira BioSciences, Inc..
U.S. Patents
Recent USPTO applications naming Pacira BioSciences, Inc.
No USPTO patent applications found for Pacira BioSciences, Inc..
Annual Financials
From PCRX's 10-K filings · XBRL
No annual XBRL figures on record for PCRX. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in PCRX's price history.
Material Events (8-K)
Corporate events filed with the SEC
About Pacira BioSciences, Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersBRISBANE, CA
IncorporatedDE
SEC CIK0001396814 ↗
Former namesPacira Pharmaceuticals, Inc., PACIRA INC, Blue Acquisition Corp